-
Je něco špatně v tomto záznamu ?
Characterization of Three Druggable Hot-Spots in the Aurora-A/TPX2 Interaction Using Biochemical, Biophysical, and Fragment-Based Approaches
PJ. McIntyre, PM. Collins, L. Vrzal, K. Birchall, LH. Arnold, C. Mpamhanga, PJ. Coombs, SG. Burgess, MW. Richards, A. Winter, V. Veverka, FV. Delft, A. Merritt, R. Bayliss,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- aurora kinasa A chemie metabolismus MeSH
- jaderné proteiny chemie metabolismus MeSH
- krystalografie rentgenová MeSH
- lidé MeSH
- ligandy MeSH
- mapy interakcí proteinů účinky léků MeSH
- objevování léků MeSH
- proteiny asociované s mikrotubuly chemie metabolismus MeSH
- proteiny buněčného cyklu chemie metabolismus MeSH
- simulace molekulového dockingu MeSH
- thiazolidiny chemie farmakologie MeSH
- vazba proteinů účinky léků MeSH
- vazebná místa účinky léků MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
The mitotic kinase Aurora-A and its partner protein TPX2 (Targeting Protein for Xenopus kinesin-like protein 2) are overexpressed in cancers, and it has been proposed that they work together as an oncogenic holoenzyme. TPX2 is responsible for activating Aurora-A during mitosis, ensuring proper cell division. Disruption of the interface with TPX2 is therefore a potential target for novel anticancer drugs that exploit the increased sensitivity of cancer cells to mitotic stress. Here, we investigate the interface using coprecipitation assays and isothermal titration calorimetry to quantify the energetic contribution of individual residues of TPX2. Residues Tyr8, Tyr10, Phe16, and Trp34 of TPX2 are shown to be crucial for robust complex formation, suggesting that the interaction could be abrogated through blocking any of the three pockets on Aurora-A that complement these residues. Phosphorylation of Aurora-A on Thr288 is also necessary for high-affinity binding, and here we identify arginine residues that communicate the phosphorylation of Thr288 to the TPX2 binding site. With these findings in mind, we conducted a high-throughput X-ray crystallography-based screen of 1255 fragments against Aurora-A and identified 59 hits. Over three-quarters of these hits bound to the pockets described above, both validating our identification of hotspots and demonstrating the druggability of this protein-protein interaction. Our study exemplifies the potential of high-throughput crystallography facilities such as XChem to aid drug discovery. These results will accelerate the development of chemical inhibitors of the Aurora-A/TPX2 interaction.
Diamond Light Source Harwell Science and Innovation Campus Didcot OX11 0DE United Kingdom
LifeArc Stevenage Bioscience Catalyst Gunnels Wood Road Stevenage SG1 2FX United Kingdom
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18016275
- 003
- CZ-PrNML
- 005
- 20180518130031.0
- 007
- ta
- 008
- 180515s2017 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1021/acschembio.7b00537 $2 doi
- 035 __
- $a (PubMed)29045126
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a McIntyre, Patrick J $u Department of Molecular and Cell Biology, Henry Wellcome Building, University of Leicester , Leicester, LE1 9HN, United Kingdom.
- 245 10
- $a Characterization of Three Druggable Hot-Spots in the Aurora-A/TPX2 Interaction Using Biochemical, Biophysical, and Fragment-Based Approaches / $c PJ. McIntyre, PM. Collins, L. Vrzal, K. Birchall, LH. Arnold, C. Mpamhanga, PJ. Coombs, SG. Burgess, MW. Richards, A. Winter, V. Veverka, FV. Delft, A. Merritt, R. Bayliss,
- 520 9_
- $a The mitotic kinase Aurora-A and its partner protein TPX2 (Targeting Protein for Xenopus kinesin-like protein 2) are overexpressed in cancers, and it has been proposed that they work together as an oncogenic holoenzyme. TPX2 is responsible for activating Aurora-A during mitosis, ensuring proper cell division. Disruption of the interface with TPX2 is therefore a potential target for novel anticancer drugs that exploit the increased sensitivity of cancer cells to mitotic stress. Here, we investigate the interface using coprecipitation assays and isothermal titration calorimetry to quantify the energetic contribution of individual residues of TPX2. Residues Tyr8, Tyr10, Phe16, and Trp34 of TPX2 are shown to be crucial for robust complex formation, suggesting that the interaction could be abrogated through blocking any of the three pockets on Aurora-A that complement these residues. Phosphorylation of Aurora-A on Thr288 is also necessary for high-affinity binding, and here we identify arginine residues that communicate the phosphorylation of Thr288 to the TPX2 binding site. With these findings in mind, we conducted a high-throughput X-ray crystallography-based screen of 1255 fragments against Aurora-A and identified 59 hits. Over three-quarters of these hits bound to the pockets described above, both validating our identification of hotspots and demonstrating the druggability of this protein-protein interaction. Our study exemplifies the potential of high-throughput crystallography facilities such as XChem to aid drug discovery. These results will accelerate the development of chemical inhibitors of the Aurora-A/TPX2 interaction.
- 650 _2
- $a aurora kinasa A $x chemie $x metabolismus $7 D064096
- 650 _2
- $a vazebná místa $x účinky léků $7 D001665
- 650 _2
- $a proteiny buněčného cyklu $x chemie $x metabolismus $7 D018797
- 650 _2
- $a krystalografie rentgenová $7 D018360
- 650 _2
- $a objevování léků $7 D055808
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ligandy $7 D008024
- 650 _2
- $a proteiny asociované s mikrotubuly $x chemie $x metabolismus $7 D008869
- 650 _2
- $a simulace molekulového dockingu $7 D062105
- 650 _2
- $a jaderné proteiny $x chemie $x metabolismus $7 D009687
- 650 _2
- $a vazba proteinů $x účinky léků $7 D011485
- 650 _2
- $a mapy interakcí proteinů $x účinky léků $7 D060066
- 650 _2
- $a thiazolidiny $x chemie $x farmakologie $7 D053778
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Collins, Patrick M $u Diamond Light Source, Harwell Science and Innovation Campus , Didcot, OX11 0DE, United Kingdom.
- 700 1_
- $a Vrzal, Lukáš $u University of Chemistry and Technology , Technická 5, Prague 6 - Dejvice, Prague, 166 28, Czech Republic. Institute of Organic Chemistry and Biochemistry , Flemingovo nám. 542/2, Prague 6, Prague, 166 10, Czech Republic.
- 700 1_
- $a Birchall, Kristian $u LifeArc (Formerly MRC Technology), Stevenage Bioscience Catalyst , Gunnels Wood Road, Stevenage, SG1 2FX, United Kingdom.
- 700 1_
- $a Arnold, Laurence H $u LifeArc (Formerly MRC Technology), Stevenage Bioscience Catalyst , Gunnels Wood Road, Stevenage, SG1 2FX, United Kingdom.
- 700 1_
- $a Mpamhanga, Chido $u LifeArc (Formerly MRC Technology), Stevenage Bioscience Catalyst , Gunnels Wood Road, Stevenage, SG1 2FX, United Kingdom.
- 700 1_
- $a Coombs, Peter J $u LifeArc (Formerly MRC Technology), Stevenage Bioscience Catalyst , Gunnels Wood Road, Stevenage, SG1 2FX, United Kingdom.
- 700 1_
- $a Burgess, Selena G $u Astbury Centre for Structural and Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds , Leeds LS2 9JT, United Kingdom.
- 700 1_
- $a Richards, Mark W $u Astbury Centre for Structural and Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds , Leeds LS2 9JT, United Kingdom.
- 700 1_
- $a Winter, Anja $u Department of Molecular and Cell Biology, Henry Wellcome Building, University of Leicester , Leicester, LE1 9HN, United Kingdom.
- 700 1_
- $a Veverka, Václav $u Institute of Organic Chemistry and Biochemistry , Flemingovo nám. 542/2, Prague 6, Prague, 166 10, Czech Republic.
- 700 1_
- $a Delft, Frank von $u Diamond Light Source, Harwell Science and Innovation Campus , Didcot, OX11 0DE, United Kingdom. Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford , Roosevelt Drive, Oxford, OX3 7DQ, United Kingdom. Department of Biochemistry, University of Johannesburg , Auckland Park, 2006, South Africa.
- 700 1_
- $a Merritt, Andy $u LifeArc (Formerly MRC Technology), Stevenage Bioscience Catalyst , Gunnels Wood Road, Stevenage, SG1 2FX, United Kingdom.
- 700 1_
- $a Bayliss, Richard $u Astbury Centre for Structural and Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds , Leeds LS2 9JT, United Kingdom.
- 773 0_
- $w MED00179502 $t ACS chemical biology $x 1554-8937 $g Roč. 12, č. 11 (2017), s. 2906-2914
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29045126 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180515 $b ABA008
- 991 __
- $a 20180518130209 $b ABA008
- 999 __
- $a ok $b bmc $g 1299899 $s 1013115
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 12 $c 11 $d 2906-2914 $e 20171030 $i 1554-8937 $m ACS chemical biology $n ACS Chem Biol $x MED00179502
- LZP __
- $a Pubmed-20180515